Pharma Q2 Preview: Lack of new US approvals to overshadow domestic revival

Amid rising regulatory risk in the sector, pharmaceutical companies are likely to post 7-8 per cent earnings growth on a 12 per cent year-on-year (YoY) revenue growth. Aggregate revenue growth would be the lowest in the last four quarters, point out analysts, who say that a decline in approvals and a lack of meaningful launches would drag the US market growth. Emkay Global pointed out in its report that weak US growth would overshadow the revival in the domestic business. It expects the revenues to grow by 12 per cent, while earnings before interest, tax, depreciation and amortization (E.....

Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.